Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Article

    August 2, 2021 | Alzheimer's 

    A glimmer of hope for Alzheimer’s patients, but at what cost?

    In her latest article for PME Magazine, Rachel Howard explores the implications for P&R decisions in EU countries following the FDA’s recent approval of Aduhelm as a treatment for Alzheimer’s disease.

    Read the full article here: https://bit.ly/3ikje2A

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    MAKING THE FIRST YEAR MATTER

    *Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded...

    Breaking the silence: It’s time to talk about the menopause

    Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.

    News:

    Senior Analytics Specialist joins Research Partnership

    ASHFIELD HEALTH LAUNCHES HEALTH INTELLIGENCE PLATFORM, GRAVITY.AI

    Dynamic data-driven solution unlocks deeper insights and powers stronger omnichannel experiences.

    Article:

    All change – how untangling human behaviour can encourage better health

    Webcast:

    Understanding changing digital behaviours: Insights needed for an effective omnichannel strategy

    News:

    Therapy Watch COVID-19 tracker

    Events:

    Patient Centricity and Engagement Conference 2021

    Webcast:

    UX beyond the website: Insights for the age of omnichannel

    News:

    MedTech Qualitative Specialist joins Research Partnership